Physician profile
Matthew E Macken
NPI 1194138818
$389.06
in general payments reported to CMS, 2019-2025
11 companies · $61.30 in 2025
The $61.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.05 · 2022: $179 · 2023: $74.38 · 2025: $61.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107 · Education: $28.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.18 |
| Education | $28.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $81.04 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $74.10 | 2022 | |
| Daiichi Sankyo INC. | $55.49 | 2021-2023 | Injectafer |
| Averitas Pharma INC. | $32.80 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $28.50 | 2025 | Trelegy Ellipta |
| Dexcom, INC. | $26.57 | 2022 | |
| Novo Nordisk INC | $24.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.62 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.20 | 2021 | |
| Amgen INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Macken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.